Concepts (266)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Women's Health | 14 | 2021 | 174 | 1.610 |
Why?
|
| Metabolic Syndrome | 6 | 2020 | 55 | 1.540 |
Why?
|
| Menopause | 9 | 2021 | 99 | 1.360 |
Why?
|
| Adiposity | 8 | 2018 | 42 | 1.350 |
Why?
|
| Intra-Abdominal Fat | 6 | 2021 | 41 | 1.170 |
Why?
|
| Obesity | 6 | 2018 | 289 | 1.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2015 | 148 | 1.020 |
Why?
|
| Cardiovascular Diseases | 8 | 2021 | 289 | 0.960 |
Why?
|
| Middle Aged | 36 | 2021 | 7915 | 0.850 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 106 | 0.830 |
Why?
|
| Ecosystem | 1 | 2023 | 24 | 0.820 |
Why?
|
| Thrombosis | 2 | 2014 | 51 | 0.770 |
Why?
|
| Female | 43 | 2021 | 12958 | 0.750 |
Why?
|
| Obesity, Abdominal | 4 | 2015 | 19 | 0.740 |
Why?
|
| Atrial Fibrillation | 2 | 2014 | 98 | 0.720 |
Why?
|
| Adrenal Gland Diseases | 2 | 2012 | 3 | 0.670 |
Why?
|
| Humans | 47 | 2023 | 22932 | 0.650 |
Why?
|
| Abdominal Fat | 3 | 2021 | 9 | 0.600 |
Why?
|
| Risk Factors | 20 | 2021 | 1971 | 0.590 |
Why?
|
| Diet Therapy | 1 | 2018 | 10 | 0.580 |
Why?
|
| Adult | 22 | 2021 | 6931 | 0.570 |
Why?
|
| Weight Reduction Programs | 1 | 2018 | 20 | 0.560 |
Why?
|
| Atherosclerosis | 3 | 2021 | 44 | 0.560 |
Why?
|
| United States | 15 | 2021 | 1765 | 0.550 |
Why?
|
| Exercise Therapy | 1 | 2018 | 84 | 0.540 |
Why?
|
| Behavior Therapy | 1 | 2018 | 85 | 0.540 |
Why?
|
| Hydrocortisone | 3 | 2012 | 29 | 0.530 |
Why?
|
| Testosterone | 2 | 2014 | 27 | 0.520 |
Why?
|
| Waist-Height Ratio | 1 | 2016 | 5 | 0.510 |
Why?
|
| Metabolic Diseases | 1 | 2016 | 7 | 0.510 |
Why?
|
| Cognition Disorders | 2 | 2020 | 692 | 0.500 |
Why?
|
| Mass Screening | 1 | 2016 | 161 | 0.450 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2014 | 30 | 0.420 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2013 | 8 | 0.390 |
Why?
|
| Prevalence | 4 | 2016 | 376 | 0.390 |
Why?
|
| Adrenal Cortex Function Tests | 1 | 2012 | 1 | 0.380 |
Why?
|
| Hemodynamics | 1 | 2012 | 54 | 0.380 |
Why?
|
| Liver Cirrhosis | 1 | 2012 | 40 | 0.370 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2009 | 5 | 0.370 |
Why?
|
| Postmenopause | 6 | 2019 | 57 | 0.370 |
Why?
|
| Longitudinal Studies | 9 | 2020 | 1046 | 0.360 |
Why?
|
| Biomarkers | 5 | 2020 | 474 | 0.360 |
Why?
|
| Follow-Up Studies | 9 | 2020 | 1412 | 0.360 |
Why?
|
| Lipoproteins, HDL | 3 | 2014 | 23 | 0.360 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2009 | 2 | 0.360 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2021 | 17 | 0.350 |
Why?
|
| Perimenopause | 3 | 2021 | 14 | 0.340 |
Why?
|
| Diastole | 1 | 2010 | 28 | 0.320 |
Why?
|
| Adrenal Insufficiency | 1 | 2009 | 1 | 0.320 |
Why?
|
| Blood Glucose | 5 | 2020 | 103 | 0.310 |
Why?
|
| Cardiomyopathies | 1 | 2010 | 25 | 0.310 |
Why?
|
| Absorptiometry, Photon | 3 | 2015 | 86 | 0.310 |
Why?
|
| Vitamin D | 1 | 2010 | 27 | 0.310 |
Why?
|
| Reproducibility of Results | 4 | 2014 | 592 | 0.300 |
Why?
|
| Algorithms | 3 | 2023 | 304 | 0.300 |
Why?
|
| Hypertension | 4 | 2021 | 163 | 0.300 |
Why?
|
| Pituitary Diseases | 1 | 2008 | 3 | 0.290 |
Why?
|
| Hypothalamic Diseases | 1 | 2008 | 8 | 0.290 |
Why?
|
| Body Mass Index | 5 | 2018 | 378 | 0.280 |
Why?
|
| Prospective Studies | 6 | 2020 | 1493 | 0.280 |
Why?
|
| Depression | 3 | 2018 | 368 | 0.280 |
Why?
|
| Socioeconomic Factors | 4 | 2023 | 257 | 0.280 |
Why?
|
| Cohort Studies | 7 | 2020 | 1417 | 0.280 |
Why?
|
| Male | 13 | 2020 | 12460 | 0.270 |
Why?
|
| Exercise | 3 | 2018 | 392 | 0.260 |
Why?
|
| Population Surveillance | 2 | 2020 | 102 | 0.260 |
Why?
|
| Risk Assessment | 3 | 2020 | 548 | 0.250 |
Why?
|
| Sensitivity and Specificity | 3 | 2014 | 442 | 0.250 |
Why?
|
| Prognosis | 3 | 2020 | 730 | 0.250 |
Why?
|
| Ketone Bodies | 1 | 2005 | 4 | 0.230 |
Why?
|
| Incidence | 5 | 2020 | 624 | 0.230 |
Why?
|
| ROC Curve | 3 | 2009 | 121 | 0.220 |
Why?
|
| Insulin | 2 | 2011 | 77 | 0.210 |
Why?
|
| Diet | 2 | 2019 | 178 | 0.210 |
Why?
|
| Aged | 11 | 2020 | 7449 | 0.210 |
Why?
|
| Chicago | 5 | 2014 | 813 | 0.210 |
Why?
|
| Economic Development | 1 | 2023 | 2 | 0.210 |
Why?
|
| Estradiol | 4 | 2021 | 52 | 0.210 |
Why?
|
| Developing Countries | 1 | 2023 | 13 | 0.210 |
Why?
|
| Pregnanediol | 2 | 2021 | 7 | 0.210 |
Why?
|
| Life Style | 2 | 2018 | 159 | 0.210 |
Why?
|
| Luteinizing Hormone | 2 | 2021 | 12 | 0.210 |
Why?
|
| Pharmacoepidemiology | 2 | 2020 | 3 | 0.200 |
Why?
|
| Atrial Appendage | 2 | 2014 | 26 | 0.200 |
Why?
|
| Energy Intake | 3 | 2019 | 77 | 0.200 |
Why?
|
| Hypoglycemic Agents | 1 | 2003 | 35 | 0.200 |
Why?
|
| Energy Metabolism | 2 | 2018 | 42 | 0.190 |
Why?
|
| Waist Circumference | 4 | 2016 | 35 | 0.190 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 168 | 0.190 |
Why?
|
| Stroke Volume | 2 | 2014 | 41 | 0.180 |
Why?
|
| Hyperglycemia | 2 | 2020 | 32 | 0.180 |
Why?
|
| Menstrual Cycle | 2 | 2021 | 19 | 0.180 |
Why?
|
| Progesterone | 1 | 2021 | 19 | 0.170 |
Why?
|
| Carotid Artery Diseases | 1 | 2021 | 13 | 0.170 |
Why?
|
| Cosyntropin | 2 | 2012 | 2 | 0.170 |
Why?
|
| Multimorbidity | 1 | 2020 | 6 | 0.160 |
Why?
|
| Insulin Resistance | 4 | 2011 | 48 | 0.160 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 88 | 0.160 |
Why?
|
| Cholesterol, HDL | 3 | 2011 | 26 | 0.160 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 42 | 0.160 |
Why?
|
| Cerebral Hemorrhage | 1 | 2020 | 103 | 0.160 |
Why?
|
| Seasons | 1 | 2019 | 18 | 0.150 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 40 | 0.150 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 88 | 0.150 |
Why?
|
| Appetite | 1 | 2018 | 4 | 0.150 |
Why?
|
| Chronic Disease | 1 | 2020 | 375 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 263 | 0.140 |
Why?
|
| Time Factors | 4 | 2020 | 1261 | 0.140 |
Why?
|
| Fractures, Bone | 1 | 2019 | 70 | 0.140 |
Why?
|
| Weight Gain | 1 | 2018 | 61 | 0.140 |
Why?
|
| Body Weight | 1 | 2018 | 129 | 0.140 |
Why?
|
| Weight Loss | 1 | 2018 | 121 | 0.130 |
Why?
|
| Sleep Wake Disorders | 1 | 2018 | 109 | 0.130 |
Why?
|
| Depressive Disorder | 1 | 2018 | 163 | 0.130 |
Why?
|
| Hormones | 1 | 2017 | 14 | 0.130 |
Why?
|
| Social Support | 1 | 2018 | 174 | 0.130 |
Why?
|
| Retrospective Studies | 5 | 2014 | 2995 | 0.130 |
Why?
|
| Beverages | 1 | 2016 | 12 | 0.130 |
Why?
|
| Cross-Sectional Studies | 3 | 2009 | 761 | 0.130 |
Why?
|
| Child | 3 | 2009 | 1157 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 439 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2014 | 577 | 0.120 |
Why?
|
| Climacteric | 1 | 2015 | 4 | 0.120 |
Why?
|
| Age Factors | 3 | 2020 | 638 | 0.120 |
Why?
|
| Estrogens | 1 | 2015 | 26 | 0.120 |
Why?
|
| False Positive Reactions | 1 | 2015 | 29 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 19 | 0.110 |
Why?
|
| Immunoassay | 1 | 2015 | 33 | 0.110 |
Why?
|
| Carbonated Beverages | 1 | 2014 | 2 | 0.110 |
Why?
|
| Research Report | 1 | 2014 | 5 | 0.110 |
Why?
|
| Sweetening Agents | 1 | 2014 | 5 | 0.110 |
Why?
|
| Waist-Hip Ratio | 1 | 2014 | 12 | 0.110 |
Why?
|
| Birth Weight | 1 | 2015 | 38 | 0.110 |
Why?
|
| Meals | 1 | 2014 | 10 | 0.110 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2015 | 32 | 0.110 |
Why?
|
| Illinois | 2 | 2013 | 221 | 0.110 |
Why?
|
| Hyperandrogenism | 1 | 2014 | 2 | 0.110 |
Why?
|
| Oligomenorrhea | 1 | 2014 | 2 | 0.110 |
Why?
|
| Self Report | 3 | 2020 | 194 | 0.110 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2014 | 31 | 0.100 |
Why?
|
| Personal Satisfaction | 1 | 2014 | 39 | 0.100 |
Why?
|
| Body Image | 1 | 2014 | 27 | 0.100 |
Why?
|
| Cognitive Dysfunction | 1 | 2021 | 737 | 0.100 |
Why?
|
| Employment | 1 | 2013 | 38 | 0.100 |
Why?
|
| Motor Activity | 2 | 2018 | 267 | 0.100 |
Why?
|
| Heart Valve Diseases | 1 | 2013 | 11 | 0.100 |
Why?
|
| Blood Pressure | 4 | 2019 | 166 | 0.100 |
Why?
|
| Neuropsychological Tests | 2 | 2021 | 865 | 0.100 |
Why?
|
| Body Fat Distribution | 1 | 2012 | 12 | 0.100 |
Why?
|
| Logistic Models | 3 | 2019 | 351 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 168 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2012 | 144 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 273 | 0.090 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 3729 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2013 | 204 | 0.090 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2011 | 2 | 0.090 |
Why?
|
| Breast Neoplasms | 2 | 2015 | 393 | 0.080 |
Why?
|
| Infant | 2 | 2009 | 483 | 0.080 |
Why?
|
| Child, Preschool | 2 | 2009 | 567 | 0.080 |
Why?
|
| Calcifediol | 1 | 2010 | 2 | 0.080 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2010 | 2 | 0.080 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2010 | 28 | 0.080 |
Why?
|
| Particle Size | 1 | 2010 | 37 | 0.080 |
Why?
|
| Pericardium | 1 | 2010 | 20 | 0.080 |
Why?
|
| Metyrapone | 1 | 2009 | 1 | 0.080 |
Why?
|
| Glucose Tolerance Test | 1 | 2009 | 13 | 0.080 |
Why?
|
| Alcohol Drinking | 1 | 2010 | 65 | 0.080 |
Why?
|
| Reference Standards | 1 | 2009 | 22 | 0.080 |
Why?
|
| Antimetabolites | 1 | 2009 | 12 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2010 | 215 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 801 | 0.080 |
Why?
|
| Follicle Stimulating Hormone | 2 | 2021 | 22 | 0.080 |
Why?
|
| Hospitals, Public | 1 | 2009 | 27 | 0.080 |
Why?
|
| Health Behavior | 1 | 2010 | 137 | 0.070 |
Why?
|
| Fasting | 1 | 2008 | 22 | 0.070 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2008 | 21 | 0.070 |
Why?
|
| Urban Population | 1 | 2009 | 127 | 0.070 |
Why?
|
| Glucocorticoids | 1 | 2008 | 58 | 0.070 |
Why?
|
| Hypercalcemia | 1 | 2007 | 7 | 0.070 |
Why?
|
| Burns | 1 | 2007 | 15 | 0.070 |
Why?
|
| Carotid Arteries | 2 | 2021 | 14 | 0.060 |
Why?
|
| Adolescent | 2 | 2009 | 1882 | 0.060 |
Why?
|
| Linear Models | 2 | 2018 | 192 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2007 | 121 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 2007 | 234 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2007 | 147 | 0.060 |
Why?
|
| Young Adult | 1 | 2009 | 1653 | 0.050 |
Why?
|
| Lamin Type A | 1 | 2004 | 2 | 0.050 |
Why?
|
| Lipodystrophy | 1 | 2004 | 1 | 0.050 |
Why?
|
| Acyltransferases | 1 | 2004 | 4 | 0.050 |
Why?
|
| GTP-Binding Protein gamma Subunits | 1 | 2004 | 3 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 47 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2015 | 219 | 0.050 |
Why?
|
| Gluconeogenesis | 1 | 2003 | 3 | 0.050 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2003 | 3 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2003 | 17 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2014 | 267 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2003 | 33 | 0.050 |
Why?
|
| Triglycerides | 2 | 2014 | 54 | 0.050 |
Why?
|
| Cognition | 1 | 2009 | 948 | 0.050 |
Why?
|
| Surveys and Questionnaires | 3 | 2015 | 1021 | 0.050 |
Why?
|
| Liver | 1 | 2003 | 135 | 0.050 |
Why?
|
| Patient Selection | 1 | 2003 | 167 | 0.050 |
Why?
|
| Ankle Brachial Index | 1 | 2021 | 2 | 0.040 |
Why?
|
| Pulse Wave Analysis | 1 | 2021 | 4 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2003 | 235 | 0.040 |
Why?
|
| Disease Progression | 1 | 2003 | 529 | 0.040 |
Why?
|
| Vasomotor System | 1 | 2021 | 3 | 0.040 |
Why?
|
| Affect | 1 | 2021 | 57 | 0.040 |
Why?
|
| Morbidity | 1 | 2020 | 50 | 0.040 |
Why?
|
| Hypertriglyceridemia | 2 | 2014 | 20 | 0.040 |
Why?
|
| Diet Surveys | 1 | 2019 | 22 | 0.040 |
Why?
|
| Propensity Score | 1 | 2019 | 33 | 0.040 |
Why?
|
| Healthy Aging | 1 | 2018 | 8 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2018 | 46 | 0.040 |
Why?
|
| Hospitalization | 1 | 2020 | 286 | 0.040 |
Why?
|
| Osteoporosis | 1 | 2019 | 73 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2018 | 227 | 0.030 |
Why?
|
| Sleep | 1 | 2020 | 268 | 0.030 |
Why?
|
| Accidental Falls | 1 | 2019 | 105 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 152 | 0.030 |
Why?
|
| Genotype | 1 | 2018 | 248 | 0.030 |
Why?
|
| Estrone | 1 | 2017 | 8 | 0.030 |
Why?
|
| Corpus Luteum | 1 | 2017 | 5 | 0.030 |
Why?
|
| Premenopause | 1 | 2017 | 11 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 15 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 15 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 3 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 62 | 0.030 |
Why?
|
| Androgens | 1 | 2014 | 7 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 286 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 481 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 125 | 0.020 |
Why?
|
| Aging | 1 | 2018 | 1102 | 0.020 |
Why?
|
| Tunica Intima | 1 | 2011 | 11 | 0.020 |
Why?
|
| Stroke | 1 | 2014 | 241 | 0.020 |
Why?
|
| Nutrition Policy | 1 | 2010 | 8 | 0.020 |
Why?
|
| France | 1 | 2010 | 13 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 40 | 0.020 |
Why?
|
| Vegetables | 1 | 2010 | 21 | 0.020 |
Why?
|
| Fruit | 1 | 2010 | 24 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2010 | 36 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2010 | 37 | 0.020 |
Why?
|
| Biological Availability | 1 | 2009 | 14 | 0.020 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2009 | 16 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 190 | 0.020 |
Why?
|
| Albumins | 1 | 2007 | 18 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2015 | 2941 | 0.020 |
Why?
|
| Knowledge | 1 | 2007 | 12 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2007 | 29 | 0.020 |
Why?
|
| Lipids | 1 | 2007 | 45 | 0.020 |
Why?
|
| Length of Stay | 1 | 2007 | 298 | 0.010 |
Why?
|
| Consanguinity | 1 | 2004 | 2 | 0.010 |
Why?
|
| Pennsylvania | 1 | 2004 | 6 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2004 | 7 | 0.010 |
Why?
|
| 1-Acylglycerol-3-Phosphate O-Acyltransferase | 1 | 2004 | 1 | 0.010 |
Why?
|
| Hyperinsulinism | 1 | 2004 | 4 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 2004 | 4 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2004 | 24 | 0.010 |
Why?
|
| RNA Splice Sites | 1 | 2004 | 2 | 0.010 |
Why?
|
| Calcium | 1 | 2007 | 370 | 0.010 |
Why?
|
| Exons | 1 | 2004 | 28 | 0.010 |
Why?
|
| Homozygote | 1 | 2004 | 13 | 0.010 |
Why?
|
| Haplotypes | 1 | 2004 | 40 | 0.010 |
Why?
|
| Alleles | 1 | 2004 | 165 | 0.010 |
Why?
|
| Phenotype | 1 | 2004 | 260 | 0.010 |
Why?
|